Writing session with
O. Varenne & C. Dupic
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in patients ≥75 years old, suffering from stable angina, silent ischemia (1 month DAPT) or acute coronary syndromes (6 months DAPT) related to significant coronary artery disease and requiring percutaneous coronary intervention.
- Composite rate of Major Cardiovascular and Cerebrovascular Events (all-cause death, myocardial infarction, stroke, ischemia-driven target lesion revascularization) at one year
- Full Services including Corelab, CEC & DSMB Management – CERIC Sponsor
Belgium, Finland, France, Italy, Latvia, Macedonia, Spain, Switzerland and UK managed by CERC.
43 centers managed by CERC.
- Primary Endpoint results at TCT 2017 by Prof Olivier Varenne and simultaneous publication in Lancet.
Presentation of results : Late Breaking Trial at TCT 2017 (Colorado Convention Center, Denver, Colorado)Session : Main Arena III,
Title: SENIOR: A Randomized Trial of a Bioresorbable Polymer-Based Metallic DES vs a BMS with Short DAPT in Patients With Coronary Artery Disease Older than 75 Years
Date: Wednesday, November 1st, 2017 | 11:00:00 AM – 11:12:00 AM
- Investigator meeting : Tuesday 31st october